Literature DB >> 16409426

Association between unplanned readmission rate and volume of breast cancer operation cases.

H-S Ahn1, S-J Yoon, H-Y Jo, H-Y Lee, J Lee, H-J Seo.   

Abstract

This study was conducted to investigate the relationship between unplanned readmission and breast cancer operation cases, with the assumption that the rate of unplanned readmission within 30 days of surgery was solely due to postsurgical complications. We divided hospitals into three categories based on breast cancer operation cases: low-volume hospitals (< or =50 annual procedures), medium-volume hospitals (51-99 annual procedures) and high-volume hospitals (> or =100 annual procedures). The medical records of 1351 subjects in 24 hospitals were investigated. We found unplanned readmission rates were significantly higher in hospitals with a lower surgical volume. From these three groups, a sample consisting of 1351 patients was created and 17 unplanned readmission cases (1.2%) were reported. Of these 17 cases, 12 (70.59%) cases were from low-volume hospitals. The present results indicate that unplanned readmission within 30 days following discharge is an important adverse outcome in breast cancer surgery.

Entities:  

Mesh:

Year:  2006        PMID: 16409426     DOI: 10.1111/j.1368-5031.2006.00736.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  2 in total

1.  Unplanned surgical reoperations as a quality indicator in pediatric tertiary general surgical specialties: Associated risk factors and hospitalization, a retrospective case-control analysis.

Authors:  Ang Li; Hai Zhu; Hong Zhou; Jianxia Liu; Yuhua Deng; Qingshuang Liu; Chunbao Guo
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

2.  MicroRNA-423 Drug Resistance and Proliferation of Breast Cancer Cells by Targeting ZFP36.

Authors:  Wenfei Xia; Yun Liu; Yaying Du; Teng Cheng; Xiaopeng Hu; Xingrui Li
Journal:  Onco Targets Ther       Date:  2020-01-24       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.